Patient Expanded Access Program News Today

LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd ("Tiziana", NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality

- Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response - FDA allows for continued enrollment under

By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT On May 25, 2021, Tiziana Life Sciences PLC (NASDAQ:TLSA ) (LSE:TILS) announced that it had initiated a trial through the Individual Patient Expanded Access Program (EAP) of foralumab in a Secondary Progressive Multiple Sclerosis (SPMS) patient. This follows a previous release in late March that first introduced the effort that was cleared under the EAP. The first...

Message : Required fields Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program ● The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical resp...

(0) How great is this? As someone who gave himself an injection in his thigh for many years and received IV infusions for many more, an MS antibody treatment sprayed into the nose is wonderful news. T his approval only applies to one patient, however. A Phase 1 clinical trial is underway, and a Phase 2 is expected to begin later this year. I hope this nasal spray, which initially was intended to be an oral medication, proves to be safe and effective. For a first time, an immune-modulating...